Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Cost-Effectiveness of Olanzapine and Risperidone in Treatment of Patients with Behavioural and Psychological Symptoms of Dementia in Thailand

Version 1 : Received: 11 November 2020 / Approved: 12 November 2020 / Online: 12 November 2020 (10:28:50 CET)

How to cite: Thongchandee, O.; Khatab, K.; Raheem, M. Cost-Effectiveness of Olanzapine and Risperidone in Treatment of Patients with Behavioural and Psychological Symptoms of Dementia in Thailand. Preprints 2020, 2020110341 (doi: 10.20944/preprints202011.0341.v1). Thongchandee, O.; Khatab, K.; Raheem, M. Cost-Effectiveness of Olanzapine and Risperidone in Treatment of Patients with Behavioural and Psychological Symptoms of Dementia in Thailand. Preprints 2020, 2020110341 (doi: 10.20944/preprints202011.0341.v1).

Abstract

Aim: This research is aimed at examining the cost-effectiveness of olanzapine versus risperidone in dementia patients with behavioural and psychological symptoms in Thailand. Methods: An existing Markov model based on a critical review through the comprehensive literature search and a justification for the most appropriate model for a Thai setting was adapted to simulate the disease progression of patients with dementia with behavioural disturbances until their need for full-time care (FTC). The time to the FTC state was estimated by a predictive equation developed by Rive et al. (2010). The model was conducted to assess the expected costs and outcomes associated with olanzapine compared with risperidone for Thai patients with BPSD aged 60 years and above. This model performed over a five-year time horizon with a one-month cycle length based on a societal perspective. The incremental cost-effectiveness ratio was used as the estimated outcome. Sensitivity analyses were also conducted to demonstrate the robustness of the results. Results: Over 5 years, olanzapine was found to be a cost-effective therapeutic option for the treatment of behaviourally disturbed patients with dementia compared with risperidone, in Thailand from a societal perspective (ICER < THB 160,000). The model underwent extensive sensitivity analyses, which also confirmed that olanzapine was the dominant strategy following the base-case findings. Conclusions: By comparison with risperidone, the model suggests that olanzapine can be regarded as a cost-effective therapeutic strategy for the management of patients with behavioural and psychological symptoms in Thailand.

Subject Areas

Dementia; Olanzapine; Risperidone; BPSD; Markov model; Sensitivity analyses; Thailand

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.